Objective. To evaluate the relationship between fecal calprotectin (FC) and interstitial lung disease (ILD) in systemic sclerosis (SSc). Methods. The study enrolled 129 outpatients with SSc. Data about disease characteristics, in particular lung involvement, were collected and FC was measured. Results. Patients with ILD (35, 27.1%) had higher values of FC (p < 0.001). In multivariate analysis, these variables were associated with increased risk of ILD: diffuse disease subset, higher modified Rodnan skin score, longer disease duration, higher severity scores, steroid treatment, and higher FC levels, while diverticulosis was protective. Conclusion. ILD is independently associated with increased FC levels in SSc
Background: Interstitial Lung Disease (ILD) is one of the major cause of morbidity and mortality in ...
Evaluation of the relationship between esophageal involvement and interstital lung involvement in sc...
Interstitial lung disease causes major morbidity and mortality in patients with systemic sclerosis (...
Knowledge on gastrointestinal manifestations in early systemic sclerosis (SSc) is limited. We have i...
Introduction: Faecal calprotectin (FC) has been proposed to be a biomarker of gastrointestinal (GI) ...
We read with great interest the study by Marie et al, who investigated the relationship between feca...
Abstract. Andréasson K, Scheja A, Saxne T, Ohlsson B, Hesselstrand R. (Section for Rheumatology; Sec...
Systemic sclerosis (SSc) is a complex, multiorgan, autoimmune disease. Lung fibrosis occurs in ∼80% ...
Systemic sclerosis (SSc) is a connective tissue disease characterised by fibrosis of the skin and in...
In systemic sclerosis (SSc), interstitial lung disease (ILD) is common (>80%) and worsens the pro...
Systemic sclerosis (SSc) is a complex, multi-organ, autoimmune disease. Lung fibrosis occurs in ~80%...
Abstract Background Systemic sclerosis (SSc) is a rare connective tissue disease with a heterogeneou...
Interstitial lung disease (ILD) affects approximately 50% of patients with systemic sclerosis (SSc) ...
Fecal calprotectin (FC) is used to asses the presence of intestinal inflammation also in patients wi...
Background: Interstitial lung disease (ILD) is a frequent complication in progressive systemic scler...
Background: Interstitial Lung Disease (ILD) is one of the major cause of morbidity and mortality in ...
Evaluation of the relationship between esophageal involvement and interstital lung involvement in sc...
Interstitial lung disease causes major morbidity and mortality in patients with systemic sclerosis (...
Knowledge on gastrointestinal manifestations in early systemic sclerosis (SSc) is limited. We have i...
Introduction: Faecal calprotectin (FC) has been proposed to be a biomarker of gastrointestinal (GI) ...
We read with great interest the study by Marie et al, who investigated the relationship between feca...
Abstract. Andréasson K, Scheja A, Saxne T, Ohlsson B, Hesselstrand R. (Section for Rheumatology; Sec...
Systemic sclerosis (SSc) is a complex, multiorgan, autoimmune disease. Lung fibrosis occurs in ∼80% ...
Systemic sclerosis (SSc) is a connective tissue disease characterised by fibrosis of the skin and in...
In systemic sclerosis (SSc), interstitial lung disease (ILD) is common (>80%) and worsens the pro...
Systemic sclerosis (SSc) is a complex, multi-organ, autoimmune disease. Lung fibrosis occurs in ~80%...
Abstract Background Systemic sclerosis (SSc) is a rare connective tissue disease with a heterogeneou...
Interstitial lung disease (ILD) affects approximately 50% of patients with systemic sclerosis (SSc) ...
Fecal calprotectin (FC) is used to asses the presence of intestinal inflammation also in patients wi...
Background: Interstitial lung disease (ILD) is a frequent complication in progressive systemic scler...
Background: Interstitial Lung Disease (ILD) is one of the major cause of morbidity and mortality in ...
Evaluation of the relationship between esophageal involvement and interstital lung involvement in sc...
Interstitial lung disease causes major morbidity and mortality in patients with systemic sclerosis (...